(Total Views: 335)
Posted On: 01/27/2022 10:16:24 AM
Post# of 30055
.jpg)
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovirâ„¢ in the Treatment of Hospitalized COVID-19 Patients
January 27, 2022 8:23am EST
https://investor.todosmedical.com/news-events...-secondary
January 27, 2022 8:23am EST
https://investor.todosmedical.com/news-events...-secondary
(1)
(0)Scroll down for more posts â–¼
